Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Cerebral organoids: human mini brains in a dish open up new possibilities for drug development in neurodegenerative and developmental diseases

Objective

Transferring results from animal models to humans is a major bottleneck in pharmaceutical research. This is particularly true for brain disorders, including neurodegenerative and developmental diseases. Both animal models and conventional cell culture methods fail to recapitulate the complexity of the human brain and there are fundamental differences in developmental and physiological aspects between humans and the commonly used animal models. The high attrition rate of drugs for brain disorders has led major pharmaceutical companies to severely downsize their respective departments.
To overcome the inherent limitations of current in vitro and in vivo models for brain disorders, we have generated a proprietary human pluripotent stem cell-derived 3D organoid culture system, termed cerebral organoids. These cerebral organoids are ‘mini brains’ that grow in a petri dish , display discrete but interconnected brain regions and recapitulate features of human brain development. ‘Mini Brains’ can be derived from patient-specific stem cells and represent a unique opportunity for creating specific human disease models in a 3D culture.
The aim of the ‘Mini Brain’ project is to investigate the commercial feasibility of cerebral organoids as a new and highly cost-effective tool in the discovery and development of therapies for neurodegenerative and developmental diseases. The use of patient-specific cerebral organoids for drug screening and validation offers an alternative to animal experiments, reducing costs and animal use and improving reliability of results, and has the potential to decrease the cost of drug development, reduce the brain disease burden and increase the rate of approved drugs for brain disorders.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2015-PoC

See all projects funded under this call

Host institution

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
DR BOHRGASSE 3
1030 WIEN
Austria

See on map

Region
Ostösterreich Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 150 000,00

Beneficiaries (1)

My booklet 0 0